News

Show
news from

Slingshot Therapeutics strengthens its team through the appointment of Ed Savory as Head of Chemistry

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors

iOnctura commences randomised Phase I/II study in non-small cell lung cancer

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation

Load more

Search